Paraoxonase gene polymorphisms and coronary reactivity in young healthy men

Malin, Riikka; Knuuti, Juhani; Janatuinen, Tuula; Laaksonen, Reijo; Vesalainen, Risto; Nuutila, Pirjo; Jokela, Hannu; Laakso, Juha; Jaakkola, Olli; Solakivi, Tiina; Lehtimäki, Terho

doi:10.1007/s001090100232

Cited by 23 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(39) In addition, Blatter-Garin et al reported that homozygosity for the 55Leu allele of PON1 is an independent risk factor for CHD in non-insulin-dependent diabetics (44), which is supported by other studies (74, 128). In contrast, some studies conducted in patient groups of different ethnicities found no significant association between the 55 polymorphism and the presence of CHD (15,214,291,358).…”

Section: Pons Polymorphisms and Coronary Artery Diseasementioning

confidence: 82%

The Human Paraoxonase Gene Cluster As a Target in the Treatment of Atherosclerosis

She

Chen

Yan

et al. 2012

Antioxidants & Redox Signaling

View full text Add to dashboard Cite

The paraoxonase (PON) gene cluster contains three adjacent gene members, PON1, PON2, and PON3. Originating from the same fungus lactonase precursor, all of the three PON genes share high sequence identity and a similar b propeller protein structure. PON1 and PON3 are primarily expressed in the liver and secreted into the serum upon expression, whereas PON2 is ubiquitously expressed and remains inside the cell. Each PON member has high catalytic activity toward corresponding artificial organophosphate, and all exhibit activities to lactones. Therefore, all three members of the family are regarded as lactonases. Under physiological conditions, they act to degrade metabolites of polyunsaturated fatty acids and homocysteine (Hcy) thiolactone, among other compounds. By detoxifying both oxidized low-density lipoprotein and Hcy thiolactone, PONs protect against atherosclerosis and coronary artery diseases, as has been illustrated by many types of in vitro and in vivo experimental evidence. Clinical observations focusing on gene polymorphisms also indicate that PON1, PON2, and PON3 are protective against coronary artery disease. Many other conditions, such as diabetes, metabolic syndrome, and aging, have been shown to relate to PONs. The abundance and/or activity of PONs can be regulated by lipoproteins and their metabolites, biological macromolecules, pharmacological treatments, dietary factors, and lifestyle. In conclusion, both previous results and ongoing studies provide evidence, making the PON cluster a prospective target for the treatment of atherosclerosis. Antioxid. Redox Signal. 16, 597-632.

show abstract

Section: Pons Polymorphisms and Coronary Artery Diseasementioning

confidence: 82%

The Human Paraoxonase Gene Cluster As a Target in the Treatment of Atherosclerosis

She

Chen

Yan

et al. 2012

Antioxidants & Redox Signaling

View full text Add to dashboard Cite

show abstract

“…The PON1 has also been shown to metabolize a number of drugs and prodrugs via its lactonase activity 14 . Serum PON1 activity is shown to be associated with modulation of endothelial functions and regulation of coronary vasomotor tone 11,15 . Increased incidence of subclinical atherosclerosis in carotid arteries has been reported in patients with CHB 16 .…”

Section: Discussionmentioning

confidence: 99%

Association of paraoxonase activity and atherosclerosis in patients with chronic hepatitis B

Karsen¹,

Binici²,

Sünnetçioğlu³

et al. 2012

Af Hlth Sci

View full text Add to dashboard Cite

Background: The hepatitis B virus is a significant pathogen that causes cirrhosis, and hepatocellular cancer as a result of the damage it causes to liver cells. Its infection affects more than 400 million people globally. Although there is an effective vaccine and treatment methods, almost 1, 000, 000 people die every year. Objective: To investigate paraoxonase and arylesterase activities along with oxidative status parameters and serum lipid levels, and to find out if there is any increased susceptibility to atherogenesis. Methods: Thirty-four subjects with chronic hepatitis B and 39 healthy subjects as control were enrolled in the study. Age, body mass index and gender, Serum Triglycerides (TG), High-density Lipoprotein (HDL) and Low-Density lipoprotein (LDL) levels, serum paraoxonase-1 and arylesterase activities were determined. Oxidative and antioxidative statuses were evaluated by measuring serum-free sulfhydryl groups, lipid hydroperoxide levels, total antioxidant capacity, total oxidant status, and oxidative stress index. Results: Serum TG and LDL levels were higher while serum HDL levels were lower in patients with chronic hepatitis B than in controls but the differences did not reach statistical significance. Serum paraoxonase-1 and arylesterase activities, plasma free sulfhydryl groups, and total antioxidant capacity were significantly lower in patients than in controls (p=0.018, p=0.005, p<0.001, p=0.037 respectively), while lipid hydroperoxide, total oxidant status, and oxidative stress index were significantly higher (for all p<0.001). Conclusion:The diminution in the paraoxonase-1 and arylesterase activities could contribute to the accelerated development of atherosclerosis in patients with chronic hepatitis B.

show abstract

“…Several studies have suggested that the PON1 Q192R polymorphism is associated with coronary vasomotor tone (8,9).…”

Section: Introductionmentioning

confidence: 99%

Impact of Paraoxonase Polymorphism (Q192R) on Endothelial Function in Intact Coronary Circulation

et al. 2006

View full text Add to dashboard Cite

Paraoxonase gene polymorphisms and coronary reactivity in young healthy men

Cited by 23 publications

References 31 publications

The Human Paraoxonase Gene Cluster As a Target in the Treatment of Atherosclerosis

The Human Paraoxonase Gene Cluster As a Target in the Treatment of Atherosclerosis

Association of paraoxonase activity and atherosclerosis in patients with chronic hepatitis B

Impact of Paraoxonase Polymorphism (Q192R) on Endothelial Function in Intact Coronary Circulation

Contact Info

Product

Resources

About